Assembly Biosciences
View On-Demand

On The Cusp Of A Cure For Hepatitis B

About the Event

The Hepatitis B Virus (HBV) infects 270 million people globally and complications caused by HBV kill close to 1 million people per year.

Given the scope and urgency of the problem, Assembly Bio (NASDAQ: ASMB) has several programs in its pipeline for curing HBV. A triple combo trial is currently in Phase 2 and an a novel oral core inhibitor drug will enter clinical trials this year.

Assembly Bio CEO, Dr. John McHutchison led the successful development of a cure for Hepatitis C. Joining him is a team with over 80 years of experience in treating HCV, HIV, and HBV. In addition to an experienced executive team, the company’s board of directors includes Nobel Laureate, Sir Michael Houghton, PhD.

Join this webinar to hear from the Dr. McHutchison as he discusses the company’s three-tiered strategic approach to curing HBV and the major inflection points that are coming this year and next.

View On Demand Webinar


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.